Appetite and weight in the product information
The US and Canadian rates come from the same two placebo-controlled trials, which the US label numbers Trial 1 and Trial 6 and Canada calls PIONEER 1 and PIONEER 8 [1][3]. Canada also lists weight decrease as a separate reaction, and Europe gives frequency classes for both [2][3].
| Source | Placebo | 7 mg | 14 mg |
|---|---|---|---|
| US PI, Table 2: decreased appetite [1] | 1% | 6% | 9% |
| Canadian PM, Table 3: decreased appetite [3] | 0.8% | 5.9% | 9.0% |
| Canadian PM, Table 3: weight decreased [3] | 0.3% | 0.6% | 1.4% |
| EU SmPC 4.8 [2] | — | Decreased appetite: common; weight decreased: uncommon | — |
Small percentages, a large ratio
In absolute terms, decreased appetite sits mid-table; more people reported nausea or stomach pain [1]. What sets it apart is the placebo column: only 1 in 100 people on placebo reported eating less, so the tablet groups were six and nine times higher [1]. The label gives no timing for it. Its sentence about the escalation period names nausea, vomiting and diarrhoea, not appetite [1].
How Europe explains it
The US label describes semaglutide’s action in terms of blood sugar: more insulin and less glucagon when glucose is high, and a small delay in stomach emptying after meals [1]. It does not describe an appetite effect. The European summary goes further. It says GLP-1 acts on appetite as well as glucose, that these effects run through receptors in the pancreas and the brain, and that semaglutide reduces body weight and fat through lower energy intake and reduced appetite, and lowers the preference for high-fat foods [2].
So a smaller appetite on Rybelsus® is an expected pharmacological effect, not only a side effect. Whether a particular change in eating is welcome or a problem depends on your situation, which is a question for your care team.
What happened to weight in the trials
In Trial 1, a 26-week study in 703 adults whose diabetes was not controlled by diet and exercise, average weight changed by −1.4 kg on placebo, −2.3 kg on 7 mg and −3.7 kg on 14 mg; against placebo, the difference on 7 mg had a confidence interval crossing zero [1]. In the four-year SOUL trial (the US label’s Trial 7), weight at week 104 had fallen by 4.22 kg on oral semaglutide against 1.27 kg on placebo [2].
These are trial results. In the US, Rybelsus® is approved for adults with type 2 diabetes, for glucose control and for cutting the risk of major heart and stroke events when that risk is high. Weight loss is not one of its uses [1].
What reports from everyday use show
In a 2024 study combining tablet and injection reports to the US FDA, decreased appetite was the fourth most reported term, with 1,456 reports [5]. A separate analysis of 2,398 reports for the tablets alone flagged early satiety and abnormal weight loss as signals that stood out despite small numbers; abnormal weight loss appeared in 6 reports [4]. Reports cannot show how often this happens or prove cause [4][5].
Eating less with other diabetes medicines
Taking the tablets with a sulfonylurea or insulin raises the risk of low blood sugar, including severe episodes, and the label says a lower dose of those medicines may reduce it [1]. Europe classes low blood sugar with insulin or a sulfonylurea as very common [2]. NIH adds that not eating enough carbohydrate, or skipping or delaying meals, can push blood sugar too low for people on these medicines, and that alcohol without food makes this worse [7].
The tablet also shapes the morning: nothing to eat or drink for at least 30 minutes after it [1]. If a smaller appetite means your first meal slips later or shrinks, raise it with your care team, especially if you use insulin or a sulfonylurea.
Other reasons appetite drops
MedlinePlus notes that any illness can reduce appetite and that it is often seen in older adults [6]. It lists sadness, depression or grief, long-term liver, kidney, lung or heart disease, an underactive thyroid, early pregnancy, some medicines such as antibiotics, codeine and morphine, and some cancers among causes [6]. It suggests keeping a record of everything you eat and drink for a day or more, which your provider can use as a diet history [6].
Rybelsus® and Ozempic® are registered trademarks of Novo Nordisk A/S. PepLabo is not affiliated with or endorsed by Novo Nordisk.
When to get help
| Sign | Who to contact | How fast | Source |
|---|---|---|---|
| Confusion, a seizure or passing out, especially with insulin or a sulfonylurea | Emergency services (911); severe low blood sugar | Emergency | Rybelsus® PM [3] |
| Shakiness, sweating, hunger, fast heartbeat or confusion | Treat low blood sugar as you were taught, then tell your prescriber | Today | Rybelsus® Medication Guide [1] |
| Eating very little because of nausea, vomiting or diarrhoea that does not go away | Your prescriber, right away | Today | Rybelsus® Medication Guide [1] |
| Low appetite together with signs of depression, or with alcohol or drug use | Medical help | Today | MedlinePlus [6] |
| Losing more than 4.5 kg (10 pounds) without trying | Your healthcare provider | At your next appointment | MedlinePlus [6] |
| A change in eating or weight while on insulin or a sulfonylurea | Your prescriber at your next contact | At your next appointment | Rybelsus® Medication Guide [1] |
